<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03689478</url>
  </required_header>
  <id_info>
    <org_study_id>CRE Ref. No. 2018.206</org_study_id>
    <nct_id>NCT03689478</nct_id>
  </id_info>
  <brief_title>Use of Immediate Hyperthermic Intravesical Chemotherapy Following TURBT</brief_title>
  <acronym>I-HIVEC</acronym>
  <official_title>A Pilot Study on the Use of Immediate Hyperthermic Intravesical Chemotherapy Following Transurethral Resection of Bladder Tumour (I-HIVEC Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective single-arm pilot study investigating the safety and feasibility of
      giving hyperthermic intravesical chemotherapy immediately following transurethral resection
      of bladder tumour.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Combat Bladder Recirculation System (BRS) is a CE marked device which has been used in
      over 200 sites in Europe. It is an aluminum heat exchanger that allows hyperthermic
      intravesical chemotherapy (HIVEC) at 43±0.2 degrees for patients with bladder cancer.
      Previous studies showed that the Combat BRS could warm the entire bladder wall to the target
      temperature with excellent safety parameters. The flow rates and pressure levels are kept low
      during the HIVEC treatment. A previous study has demonstrated the safety and tolerability of
      HIVEC as a maintenance therapy for patients with non-muscle-invasive bladder cancer (NMIBC),
      and two randomized controlled trials are underway to demonstrate its efficacy in terms of
      disease recurrence and progression. On the other hand, the use of HIVEC immediately following
      transurethral resection of bladder tumour (TURBT) remains largely unexplored. It is the
      investigators' current practice to give intravesical mitomycin C (MMC) to all patients who
      have endoscopically NMIBC with complete resection, provided that there are no bladder
      perforations being noted. In this study, the investigators shall evaluate the safety and
      feasibility of hyperthermia in addition to the current practice of intravesical MMC alone
      immediately following TURBT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective single-arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-day complications</measure>
    <time_frame>Thirty days after the experimental treatment</time_frame>
    <description>Complications which occur within 30 days after the experimental treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hyperthermic intravesical chemotherapy instillation rate</measure>
    <time_frame>One day after surgery</time_frame>
    <description>Rate of hyperthermic intravesical chemotherapy instillation given after the operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of urethral catheterisation</measure>
    <time_frame>Two days after the experimental treatment</time_frame>
    <description>Duration of urethral catheterisation after the experimental treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of bladder irrigation</measure>
    <time_frame>One day after the experimental treatment</time_frame>
    <description>Rate of bladder irrigation given after the experimental treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of bladder irrigation</measure>
    <time_frame>Two days after the experimental treatment</time_frame>
    <description>Duration of bladder irrigation after the experimental treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>Three days after the experimental treatment</time_frame>
    <description>Duration of hospital stay for the experimental treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Hyperthermia</condition>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>Hyperthermic intravesical chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravesical instillation of 40mg mitomycin C at 43 degrees for 60 minutes immediately after transurethral resection of bladder tumour</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperthermic intravesical chemotherapy</intervention_name>
    <description>Intravesical instillation of 40mg mitomycin C at 43 degrees for 60 minutes immediately after transurethral resection of bladder tumour</description>
    <arm_group_label>Hyperthermic intravesical chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or above with informed consent

        Exclusion Criteria:

          -  ECOG performance status ≥2

          -  ASA 4 or above

          -  History of bleeding disorder

          -  Any use of anti-coagulants

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeremy YC Teoh, MBBS</last_name>
    <phone>+852 3505 2625</phone>
    <email>jeremyteoh@surgery.cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jenny SY Yip, MPH</last_name>
    <phone>+852 3505 1663</phone>
    <email>siuying@surgery.cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy YC Teoh</last_name>
    </contact>
    <investigator>
      <last_name>Jeremy YC Teoh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter KF Chiu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chi-Fai Ng</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chi-Hang Yee</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7. Epub 2006 Jan 17.</citation>
    <PMID>16442208</PMID>
  </reference>
  <reference>
    <citation>Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.</citation>
    <PMID>27324428</PMID>
  </reference>
  <reference>
    <citation>Schooneveldt G, Bakker A, Balidemaj E, Chopra R, Crezee J, Geijsen ED, Hartmann J, Hulshof MC, Kok HP, Paulides MM, Sousa-Escandon A, Stauffer PR, Maccarini PF. Thermal dosimetry for bladder hyperthermia treatment. An overview. Int J Hyperthermia. 2016 Jun;32(4):417-33. doi: 10.3109/02656736.2016.1156170. Epub 2016 May 1. Review.</citation>
    <PMID>27132465</PMID>
  </reference>
  <reference>
    <citation>Owusu RA, Abern MR, Inman BA. Hyperthermia as adjunct to intravesical chemotherapy for bladder cancer. Biomed Res Int. 2013;2013:262313. doi: 10.1155/2013/262313. Epub 2013 Sep 1. Review.</citation>
    <PMID>24073396</PMID>
  </reference>
  <reference>
    <citation>Kok HP, Wust P, Stauffer PR, Bardati F, van Rhoon GC, Crezee J. Current state of the art of regional hyperthermia treatment planning: a review. Radiat Oncol. 2015 Sep 17;10:196. doi: 10.1186/s13014-015-0503-8. Review.</citation>
    <PMID>26383087</PMID>
  </reference>
  <reference>
    <citation>Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC. Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res. 1981 Mar;41(3):1096-9.</citation>
    <PMID>7459853</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Jeremy Yuen Chun TEOH</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Hyperthermic intravesical chemotherapy</keyword>
  <keyword>Bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

